Perspective Therapeutics Announced The First Shipment And Patient Dosing From Its Second Manufacturing Facility For The Production Of Its 203Pb- And 212Pb-labeled Radiopharmaceuticals

Located in Somerset, New Jersey, this facility is now operational to supply investigational products to support VMT-α-NET clinical studies, in addition to the Coralville, Iowa facility which has been producing the Company's investigational products for over 15 months. With three manufacturing suites that can meet Current Good Manufacturing Practice (cGMP) requirements, the Somerset facility is expected to have the capacity to meet future clinical trial and commercial demands at major cancer treatment centers throughout the Northeastern U.S. Until the close of its acquisition by Perspective in March 2024, this facility was operated by Lantheus Holdings, Inc., the leading radiopharmaceutical-focused company. This facility previously produced Azedra, which contained a form of radioactive iodine and received approval from the U.S. Food & Drug Administration (FDA) in 2018 for the treatment of rare tumors of the adrenal gland.